Paracetamol/Codeína Farmalider

Active Ingredient:: Paracetamol, Codeine Phosphate Hemihydrate
Origin:: EU

Paracetamol/Codeína Farmalider (Paracetamol, Codeine Phosphate Hemihydrate)

International sale not permitted. Listed for the domestic market and B2B only.

Paracetamol, the active ingredient in Paracetamol/Codeína Farmalider, is an analgesic and antipyretic presented as a combination tablet for oral use. It treats mild to moderate pain and fever in adults and children when used with codeine. GNH India supplies Paracetamol/Codeína Farmalider as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH India supplies Paracetamol/Codeína Farmalider as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Farmalider, S.A.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Paracetamol/Codeína Farmalider is used for pain relief and fever reduction within the musculoskeletal and injury‑related pathways.

Acute musculoskeletal pain: provides stronger analgesia than paracetamol alone, helping patients resume daily activities.
Post‑operative pain: assists in managing moderate pain after surgical procedures.
Dental pain: reduces pain intensity following dental extractions or procedures.
Fever associated with infection: lowers elevated body temperature when antipyretic therapy is needed.
Headache (including tension‑type): alleviates moderate headache symptoms when simple analgesics are insufficient.

How It Works

Paracetamol/Codeína Farmalider combines paracetamol, which inhibits central cyclooxygenase enzymes to reduce prostaglandin synthesis and lower pain perception, with codeine phosphate hemihydrate, an opioid agonist that binds to µ‑opioid receptors in the central nervous system, enhancing analgesic effect through modulation of nociceptive pathways.

Side Effects

Paracetamol/Codeína Farmalider may cause a range of adverse reactions, from mild to serious.

Common Side Effects

Nausea: mild stomach upset that may occur after dosing.
Dizziness: transient light‑headedness, especially on standing.
Constipation: reduced bowel movements during treatment.
Somnolence: feeling unusually sleepy or fatigued.
Dry mouth: reduced salivation leading to a parched sensation.

Serious or Rare Side Effects

Respiratory depression: slowed breathing that can be life‑threatening.
Allergic reactions: rash, itching, swelling, or anaphylaxis.
Hepatotoxicity: liver injury, particularly with high paracetamol doses.
Dependence or misuse: potential for opioid‑related dependence with prolonged use.
Severe hypotension: marked drop in blood pressure requiring medical attention.

Precautions & Warnings

Paracetamol/Codeína Farmalider should be used with caution and according to professional guidance.

Assess liver function: avoid use in patients with severe hepatic impairment.
Evaluate respiratory status: contraindicated in patients with significant respiratory depression.
Monitor for opioid dependence: limit duration of therapy to reduce risk of misuse.
Use in pregnancy only if clearly needed: discuss risks with a healthcare provider.
Adjust in renal impairment: dose may need modification in severe kidney disease.
Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Paracetamol/Codeína Farmalider can interact with several medicines, requiring careful management.

Major Interactions (Avoid)

CNS depressants (e.g., benzodiazepines, barbiturates): may intensify sedation and respiratory depression.
MAO inhibitors: can increase risk of serotonin syndrome when combined with codeine.
Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): reduce conversion of codeine to its active metabolite, lowering analgesic efficacy.

Moderate Interactions (Monitor Closely)

Anticoagulants (e.g., warfarin): paracetamol may enhance anticoagulant effect, requiring INR monitoring.
Alcohol: combined use raises risk of liver toxicity and enhanced sedation.
Antihistamines: may increase drowsiness when taken together.

Frequently Asked Questions

Paracetamol/Codeína Farmalider is a fixed‑dose combination of paracetamol and codeine phosphate hemihydrate indicated for the relief of moderate pain and reduction of fever when a single agent does not provide adequate control.

Paracetamol acts centrally by inhibiting cyclooxygenase enzymes, which reduces prostaglandin production and lowers the perception of pain and body temperature.

The prescribed dose is determined by the treating clinician based on the patient’s age, weight, pain severity and overall health status; the prescriber sets the exact regimen.

Use during pregnancy or lactation is only recommended when clearly needed and after a risk‑benefit assessment by a healthcare professional, as both paracetamol and codeine cross the placenta and may appear in breast milk.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Compared with paracetamol alone, the addition of codeine provides stronger analgesia for moderate pain. Compared with stronger opioids, it offers a lower risk of severe respiratory depression but still requires careful monitoring for dependence.

Store the tablets below 25 °C in their original container, protecting them from moisture, heat and direct sunlight to maintain potency and stability.

The tablets are taken orally with water, usually with or after food to reduce gastrointestinal irritation, following the dosage instructions provided by the prescribing clinician.

Serious risks include respiratory depression, severe liver injury from excess paracetamol, opioid dependence, and rare allergic reactions such as anaphylaxis; patients should seek immediate medical help if these occur.

Individuals with known hypersensitivity to paracetamol or codeine, severe hepatic or renal impairment, uncontrolled respiratory disorders, or those taking prohibited interacting medicines should avoid this product.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 14 Oct 2026

Disclaimer

International sale not permitted. Listed for the domestic market and B2B only.

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.